Faculty

Back to Index
Sarmad Sadeghi, MD, PhD
Assistant Professor of Clinical Medicine
Medicine
NOR 3453 Health Sciences Campus Los Angeles
+1 323 865 3829

Overview

Dr. Sadeghi earned his medical degree from Tehran University. He then earned his Master's in Health Information Sciences from University of Texas, followed by a residency in general surgery and internal medicine. Dr. Sadeghi received his PhD in Public Health, immediately followed by a Hematology/Oncology Fellowship at Taussig Cancer Institute.

Dr. Sadeghi currently serves as the USC IRB Vice Chair, and as a California Cancer Consortium Distinguished Faculty Member. He also has a patent for Automated Medical Decision Making Utilizing Bayesian Network Domain Modeling.

Publications

Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 Jul; 35(7):459. e15-459. e24. View in: PubMed

Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. View in: PubMed

Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. View in: PubMed

Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 May 01; 123(9):1516-1527. View in: PubMed

Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 Mar 08. View in: PubMed

Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 Jan 24. View in: PubMed

Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015 Apr; 107(4). View in: PubMed

Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. View in: PubMed

Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. View in: PubMed

Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. Semin Oncol. 2012 Oct; 39(5):608-14. View in: PubMed

Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer. 2012 Jul 1; 118(13):3277-82. View in: PubMed

Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer. 2012 Jul 01; 118(13):3277-82. View in: PubMed

Cessation gf vascular endothelial growth factor-targeted t`erapy in patients with metastatac renal cell carcinoma: feasibidity and clinicad outcome. Cancer. 2012 Jul 1; 118(13):3277-82. 'prns:informatiofResourceReference>. View in: PubMed

Screening for Lynch syndrome in the general population-letter. Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. View in: PubMed

A Bayesian model for triage decision support. Int J Med Inform. 2006 May; 75(5):403-11. View in: PubMed

Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS. Stud Health Technol Inform. 2005; 116:223-8. View in: PubMed

Self-administered decision support tool for triage: results of a retrospective study. Stud Health Technol Inform. 2002; 85:45-51. View in: PubMed

Powered bySC CTSI